A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy

24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury

(2010) Casandra M. Cartagena et al.   BRAIN RESEARCH

An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells

(2010) J. F. Martin et al.   JOURNAL OF IMMUNOLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis

(2009) Unsong Oh et al.   ARCHIVES OF NEUROLOGY

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets

(2009) Sven Létourneau et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Anti-CD25 Antibodies Decrease the Ability of Human Dendritic Cells to Prime Allogeneic CD4 T Cells

(2009) K. Mnasria et al.   TRANSPLANTATION PROCEEDINGS

Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: A potential tolerogenic effect

(2008) Kaouther Mnasria et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells

(2008) K. Mnasria et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Tonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr Virus via IFN-γ

(2008) Till Strowig et al.   PLoS Pathogens

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology